HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive breast cancer has led to dramatic improvements in survival in both early and advanced settings. Despite this breakthrough, nearly all patients with metastatic HER2-positive breast cancer eventually progress on an...

ver descrição completa

Detalhes bibliográficos
Autores: Pernas, Sònia, Tolaney, Sara M.
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2019
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/171604
Acesso em linha:https://hdl.handle.net/2445/171604
Access Level:Acceso aberto
Palavra-chave:Càncer de mama
Oncologia
Breast cancer
Oncology
id ES_7bb11b42c6d6ad36cf910be3e331f81b
oai_identifier_str oai:recercat.cat:2445/171604
network_acronym_str ES
network_name_str España
repository_id_str
spelling HER2-positive breast cancer: new therapeutic frontiers and overcoming resistancePernas, SòniaTolaney, Sara M.Càncer de mamaOncologiaBreast cancerOncologyThe introduction of anti-HER2 therapies to the treatment of patients with HER2-positive breast cancer has led to dramatic improvements in survival in both early and advanced settings. Despite this breakthrough, nearly all patients with metastatic HER2-positive breast cancer eventually progress on anti-HER2 therapy due to de novo or acquired resistance. A better understanding not only of the underlying mechanisms of HER2 therapy resistance but of tumor heterogeneity as well as the host and tumor microenvironment is essential for the development of new strategies to further improve patient outcomes. One strategy has focused on inhibiting the HER2 signaling pathway more effectively with dual-blockade approaches and developing improved anti-HER2 therapies like antibody-drug conjugates, new anti-HER2 antibodies, bispecific antibodies, or novel tyrosine kinase inhibitors that might replace or be used in addition to some of the current anti-HER2 treatments. Combinations of anti-HER2 therapy with other agents like immune checkpoint inhibitors, CDK4/6 inhibitors, and PI3K/AKT/mTOR inhibitors are also being extensively evaluated in clinical trials. These add-on strategies of combining optimized targeted therapies could potentially improve outcomes for patients with HER2-positive breast cancer but may also allow de-escalation of treatment in some patients, potentially sparing some from unnecessary treatments, and their related toxicities and costs.Sage Publications Ltd2020202020192020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion16 p.application/pdfhttps://hdl.handle.net/2445/171604Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1177/1758835919833519Therapeutic Advances In Medical Oncology, 2019-03-01, Vol. 11 p. 1-16https://doi.org/10.1177/1758835919833519cc by-nc (c) Pernas, Sonia et al., 2019http://creativecommons.org/licenses/by-nc/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1716042026-05-29T05:05:01Z
dc.title.none.fl_str_mv HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
title HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
spellingShingle HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, Sònia
Càncer de mama
Oncologia
Breast cancer
Oncology
title_short HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
title_full HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
title_fullStr HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
title_full_unstemmed HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
title_sort HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
dc.creator.none.fl_str_mv Pernas, Sònia
Tolaney, Sara M.
author Pernas, Sònia
author_facet Pernas, Sònia
Tolaney, Sara M.
author_role author
author2 Tolaney, Sara M.
author2_role author
dc.subject.none.fl_str_mv Càncer de mama
Oncologia
Breast cancer
Oncology
topic Càncer de mama
Oncologia
Breast cancer
Oncology
description The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive breast cancer has led to dramatic improvements in survival in both early and advanced settings. Despite this breakthrough, nearly all patients with metastatic HER2-positive breast cancer eventually progress on anti-HER2 therapy due to de novo or acquired resistance. A better understanding not only of the underlying mechanisms of HER2 therapy resistance but of tumor heterogeneity as well as the host and tumor microenvironment is essential for the development of new strategies to further improve patient outcomes. One strategy has focused on inhibiting the HER2 signaling pathway more effectively with dual-blockade approaches and developing improved anti-HER2 therapies like antibody-drug conjugates, new anti-HER2 antibodies, bispecific antibodies, or novel tyrosine kinase inhibitors that might replace or be used in addition to some of the current anti-HER2 treatments. Combinations of anti-HER2 therapy with other agents like immune checkpoint inhibitors, CDK4/6 inhibitors, and PI3K/AKT/mTOR inhibitors are also being extensively evaluated in clinical trials. These add-on strategies of combining optimized targeted therapies could potentially improve outcomes for patients with HER2-positive breast cancer but may also allow de-escalation of treatment in some patients, potentially sparing some from unnecessary treatments, and their related toxicities and costs.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/171604
url https://hdl.handle.net/2445/171604
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1177/1758835919833519
Therapeutic Advances In Medical Oncology, 2019-03-01, Vol. 11 p. 1-16
https://doi.org/10.1177/1758835919833519
dc.rights.none.fl_str_mv cc by-nc (c) Pernas, Sonia et al., 2019
http://creativecommons.org/licenses/by-nc/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc (c) Pernas, Sonia et al., 2019
http://creativecommons.org/licenses/by-nc/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 16 p.
application/pdf
dc.publisher.none.fl_str_mv Sage Publications Ltd
publisher.none.fl_str_mv Sage Publications Ltd
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411533813972992
score 15,812429

Registros relacionados